Osel Inc.

Osel's mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat abnormal conditions resulting from a disruption of the human microbiome. In 2003, Osel was one of the first companies to receive FDA authorization to test a live bacterial therapeutic, and is a pioneer in the field of LBPs.

Our proprietary approach identifies differences between healthy and disease-related microbiomes, and leverages beneficial microbes to treat problematic disruptions or ‘dysbioses'. Osel's approach of repopulating the microbiome with beneficial bacteria helps restore healthy and protective microbiomes.

The primary focus of our work is women's health, with indications including recurrent urinary tract infections and bacterial vaginosis. Our secondary focus is disorders of the gastrointestinal tract. Our product pipeline is demonstrating exciting therapeutic potential, with two clinical stage products and ongoing clinical trials.